We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
U.S. Steel Declares Senior Secured Notes Offering Due 2025
Read MoreHide Full Article
United States Steel Corporation (X - Free Report) stated that it has initiated an offering of $700 million total principal amount of senior secured notes due 2025, which are subject to market conditions.
The company plans to employ the net proceeds from the offering to boost liquidity, strengthen balance sheet as well as for general corporate purposes. Further, the company stated that the notes will be unconditionally and fully guaranteed on a senior secured basis by all of its subsidiaries, except for certain excluded subsidiaries.
U.S. Steel ended the first quarter with cash and cash equivalents of $1,350 million, up 144% year over year. Its long-term debt rose 98.5% year over year to $4,616 million.
Shares of U.S. Steel have plunged 46.8% in the past year compared with the industry’s 35.5% decline.
U.S. Steel’s adjusted loss per share of 73 cents in the first quarter was narrower than the Zacks Consensus Estimate of a loss of 80 cents.
During first-quarter 2020, the company adjusted its footprint, strengthened its balance sheet and aggressively cut costs amid the impacts of the coronavirus pandemic as well as volatility in the oil and gas markets. These actions helped the company surpass its first-quarter view.
Also, the company granted Stelco an option to purchase a 25% stake in its Minntac iron ore mining operations for purchase price of $600 million. Notably, the move showcases the consistent execution of its strategy and delivers $100 million of incremental cash to the balance sheet in 2020. The transaction will enable U.S. Steel to record an additional $500 million of capital to support its strategy.
Zacks Rank & Key Picks
U.S. Steel currently carries a Zacks Rank #3 (Hold).
Agnico Eagle has an expected earnings growth rate of 75.3% for 2020. The company’s shares have surged 66.2% in the past year.
Scotts Miracle-Gro has an expected earnings growth rate of 17.7% for fiscal 2020. Its shares have returned 58.5% in the past year.
Barrick has an expected earnings growth rate of 64.7% for 2020. The company’s shares have surged 131.9% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
U.S. Steel Declares Senior Secured Notes Offering Due 2025
United States Steel Corporation (X - Free Report) stated that it has initiated an offering of $700 million total principal amount of senior secured notes due 2025, which are subject to market conditions.
The company plans to employ the net proceeds from the offering to boost liquidity, strengthen balance sheet as well as for general corporate purposes. Further, the company stated that the notes will be unconditionally and fully guaranteed on a senior secured basis by all of its subsidiaries, except for certain excluded subsidiaries.
U.S. Steel ended the first quarter with cash and cash equivalents of $1,350 million, up 144% year over year. Its long-term debt rose 98.5% year over year to $4,616 million.
Shares of U.S. Steel have plunged 46.8% in the past year compared with the industry’s 35.5% decline.
U.S. Steel’s adjusted loss per share of 73 cents in the first quarter was narrower than the Zacks Consensus Estimate of a loss of 80 cents.
During first-quarter 2020, the company adjusted its footprint, strengthened its balance sheet and aggressively cut costs amid the impacts of the coronavirus pandemic as well as volatility in the oil and gas markets. These actions helped the company surpass its first-quarter view.
Also, the company granted Stelco an option to purchase a 25% stake in its Minntac iron ore mining operations for purchase price of $600 million. Notably, the move showcases the consistent execution of its strategy and delivers $100 million of incremental cash to the balance sheet in 2020. The transaction will enable U.S. Steel to record an additional $500 million of capital to support its strategy.
Zacks Rank & Key Picks
U.S. Steel currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Agnico Eagle Mines Limited (AEM - Free Report) , The Scotts Miracle-Gro Company (SMG - Free Report) and Barrick Gold Corporation (GOLD - Free Report) , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Agnico Eagle has an expected earnings growth rate of 75.3% for 2020. The company’s shares have surged 66.2% in the past year.
Scotts Miracle-Gro has an expected earnings growth rate of 17.7% for fiscal 2020. Its shares have returned 58.5% in the past year.
Barrick has an expected earnings growth rate of 64.7% for 2020. The company’s shares have surged 131.9% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>